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RatsThis study investigated the subchronic toxicity of molybdenum (Mo) in Sprague–Dawley rats given
sodium molybdate dihydrate in the diet for 90 days at dose levels of 0, 5, 17 or 60 mg Mo/kgbw/day.
The study complied with OECD Test Guideline (TG) 408, with additional examination of estrus cycles
and sperm count, motility, and morphology from OECD TG 416. The overall no-observed-adverse-effect
level was 17 mg Mo/kgbw/day, based on effects on body weight, body weight gain, food conversion efﬁ-
ciency and renal histopathology (females only) at 60 mg Mo/kgbw/day. No treatment-related adverse
effects on reproductive organ weights or histopathology, estrus cycles or sperm parameters were
observed at any dose level. No adverse effects were observed in the high dose animals after the 60-
day recovery period, with the exception that male rats did not fully recover from reduced body weight.
Serum blood, liver and kidney samples were analyzed for molybdenum, copper, zinc, manganese, iron,
cobalt and selenium; high levels of molybdenum and copper were found in the serum, blood, liver and
kidneys of rats treated with 60 mg Mo/kgbw/day. In conclusion, the LOAEL and NOAEL for molybdenum
were determined to be 60 and 17 mg Mo/kgbw/day, respectively.
 2013 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Molybdenum is an essential element for humans, as well as
for animals and plants (Institute of Medicine, 2001). In humans
and other mammals, molybdenum is a key constituent of at least
three important enzymes: sulﬁte oxidase, xanthine oxidase and
aldehyde oxidase (Kisker et al., 1997). Trace levels of molybde-
num are found in a wide variety of foods, and human exposure
to molybdenum may occur via the diet, drinking water and
occupational exposure from mining operations and industrial
uses.
Various countries have issued recommendations on adequate
intake levels and minimum dietary requirements of molybdenum
(Turnlund and Friberg, 2007). For example, the USA National Acad-
emy of Sciences Food and Nutrition Board (Institute of Medicine,
2001) has estimated the average requirement of molybdenum for
adults is 34 lg/day, corresponding to about 0.5 lg/kgbw/day for a
70-kg adult, whereas the British Expert Committee on Vitaminsand Minerals has estimated molybdenum requirement in the range
100–300 lg/day (1.4–4.3 lg/kgbw/day) (Turnlund and Friberg,
2007).
Human deﬁciencies of molybdenum have not been linked to
inadequate dietary intake (Nielson, 1999; Turnlund and Friberg,
2007; European Food Safety Authority (EFSA), 2010). Reports of
molybdenum deﬁciency in humans have been limited to genetic
defects that interfere with the molybdenum cofactor’s ability to
activate molybdoenzymes and to one case of feeding molybde-
num-free total parenteral nutrition (EFSA, 2010).
The toxicity of molybdenum compounds in humans has been
observed to be low, and in general, soluble molybdenum com-
pounds (e.g., sodium molybdate dihydrate) are more toxic than
insoluble compounds (Vyskocil and Viau, 1999). The symptoms
of molybdenum toxicity in humans are reported to resemble those
of copper deﬁciency, and supplemental copper usually reverses
them. High dietary levels of molybdenum have been shown to af-
fect copper metabolism in humans, resulting in an increase in cop-
per excretion and elevated levels of plasma copper (Deosthale and
Gopalan, 1974). Thiomolybdate is a potent copper chelating agent
and has been used in humans for the treatment of Wilson’s disease,
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2000; Quagraine and Reid, 2001).
The toxicity of high dietary levels of molybdenum to cattle and
sheep has been known for many years (Ward, 1994). Excessive
molybdenum causes a condition known as ‘‘teart’’, or molybdeno-
sis, which is characterised by scouring (diarrhea), rapid loss of
weight and condition, the development of harsh, discolored coats,
and ultimately death if not treated. Toxicity occurs in cattle on pas-
tures with relatively high molybdenum contents of 20–100 ppm
compared with 3–5 ppm on ‘‘normal’’ pastures (Turnlund and Fri-
berg, 2007), and the toxicity has been shown to be associated with
reduced bioavailability of copper due to the high levels of sulfur in
the rumen which interacts with molybdenum to form thiomolyb-
dates (Ward, 1994).
Toxicity studies in rats have suggested that molybdenum can
induce testicular damage (Pandey and Singh, 2002), as well as
interfere with estrus cycles and cause developmental toxicity
(Fungwe et al., 1990). However, these studies have signiﬁcant
limitations, and these ﬁndings have not been conﬁrmed in other
studies.
The purpose of the present study was to assess the subchronic
toxicity of sodium molybdate dihydrate when administered orally
(adjusted dietary administration) to male and female rats for
90 days, followed by a recovery period of up to 60 days for the con-
trol and high dose groups. The study was performed in accordance
with OECD Test Guideline 408 (OECD, 2011). In addition, in view of
the observations on testes and estrus cycles in the published liter-
ature, it was decided to include examination of estrus cycles, anal-
ysis of various sperm parameters and detailed histopathology of
reproductive organs. Serum, whole blood and tissue levels of
molybdenum, copper and other trace elements were also
measured.2. Materials and methods
2.1. Test substance
Sodium molybdate dihydrate (Na2MoO42H2O; Lot No. 43006L;
purity >99%) was supplied by Climax Molybdenum Marketing Cor-
poration (Phoenix, AZ). The test substance was selected as a source
of molybdate ion [MoO4]2 that would be representative of soluble
molybdenum(VI) compounds that give rise to molybdate ions un-
der physiological conditions. Sodium molybdate dihydrate may
be expressed in terms of molybdenum equivalents by dividing by
2.5 (the ratio of the molecular weights of sodium molybdate dihy-
drate and molybdenum is 242/95). For example, 50 mg of sodium
molybdate dihydrate is equivalent to 20 mg of molybdenum. The
doses used for this study are expressed herein as mg Mo/kgbw/day.
For dietary administration, the test substance was admixed into
Certiﬁed Rodent Diet (No. 2016C; Harlan Teklad, Madison, WI).
Analysis of the diet did not reveal any contaminants which would
be expected to interfere with the studies. For the 90-day study, die-
tary dose formulations were prepared once weekly for the ﬁrst
4 weeks of the study, then every other week for the rest of the
treatment period to achieve the target dose levels in mg Mo/kgbw/
day. Dietary dose formulations were stored at room temperature
under low humidity conditions when not in use. Homogeneity of
the dietary dose formulations was conﬁrmed, and stability was
conﬁrmed to be at least 5 weeks. Analysis of this basal control diet
showed that the mean content of molybdenum and copper was
906.5 lg/kg and 14.23 mg/kg dry weight, respectively. Based on
this concentration of molybdenum in the control diet and the mea-
sured rate of food consumption, the control group animals received
a mean exposure to molybdenum of approximately 0.08 mg Mo/
kgbw/day.2.2. Animals and husbandry
Male and female outbred albino rats (Crl:CD(SD)IGS BR, VAF/
Plus Sprague–Dawley derived) were used. The animals used for
the 90-day study were supplied by Charles River Laboratories,
Kingston, NY, USA. They were received at the test facility at
approximately 7 weeks of age and stabilized for 2–2.5 weeks, dur-
ing which they were examined for suitability for the study, before
commencing treatment. At the start of dosing, at approximately
9 weeks of age, average body weight of the males was 338.4 g
(range 309.8–377.6 g) and of the females was 229.6 g (range
187.9–263.5 g).
Animals were individually housed in elevated, stainless steel,
wire mesh cages, maintained in rooms under a 12 h light/dark cy-
cle, with a daily average temperature range of 19–23 C and a daily
average relative humidity range of 34–49%. Feed was available
without restriction. Tap water (New Jersey-American Water Com-
pany, Cherry Hill, NJ) was available without restriction via an auto-
mated watering system. Water analysis did not reveal any
contaminants which would be expected to interfere with the
study.
2.3. Study design
The 90 day toxicity study was performed at Huntingdon Life
Sciences (HLS; East Millstone, NJ) in compliance with Good Labora-
tory Practice (GLP) and in accordance with OECD Guideline 408
(OECD, 2011). In addition, in view of the observations on testes
and estrus cycles in the published literature, it was decided to in-
clude examination of estrus cycles, analysis of various sperm
parameters and detailed histopathology of reproductive organs as
described in the OECD Guideline 416 for a two-generation repro-
duction toxicity study.
Sodium molybdate dihydrate was given by dietary administra-
tion to male and female rats for 91 and 92 consecutive days,
respectively. Rats were assigned to groups using a computerized
random sort program so that body weight means for each group
were comparable as follows: Groups 1 (control) and Group 4 (high
dose) contained 20 animals/sex/group, and Groups 2 (low dose)
and 3 (middle dose) contained 10 animals/sex/group. At the end
of the 90-day treatment period, 10 animals/sex/group were nec-
ropsied. The remaining 10 animals/sex/group in Groups 1 and 4
were continued on untreated diet for up to 60 days. At the end of
the recovery period, they were necropsied.
In the 90-day study, the target doses for Groups 1, 2, 3 and 4
were 0, 5, 17 and 60 mg Mo/kgbw/day, respectively. The dose levels
were selected based on the results of a 28-day range ﬁnding study,
conducted at the same laboratory, in which sodium molybdate
dihydrate was given to groups of 5 rats/sex/group in the diet or
by gavage (once or twice daily) for 28 consecutive days at dose lev-
els of 0, 4, or 20 mg Mo/kgbw/day. Also, in the range-ﬁnder study,
blood was taken from the jugular vein from 5 rats/sex/group/time
point on day 27 (dietary administration groups) or day 28 (gavage
administration groups) at ﬁve time intervals in order to study
blood levels of molybdenum.
There was no mortality or treatment-related clinical signs in
any of the groups of rats in the range-ﬁnder study. Decreases in
body weight (8% decrease on day 28; not statistically signiﬁcant;
n = 5) and body weight gain (19% decrease on day 28; p < 0.05 at
most time intervals; n = 5) were observed among males given the
high dose (20 mg Mo/kgbw/day) in the diet. In females, no effect
on body weight or body weight gain was observed at any dose le-
vel. There were no convincing treatment-related effects on organ
weights or macroscopic or microscopic ﬁndings.
Since little evidence of toxicity was found in the range ﬁnder
study, it was decided to use a higher dose range in the 90-day
F.J. Murray et al. / Regulatory Toxicology and Pharmacology 70 (2014) 579–588 581study of 0, 5, 17 and 60 mg Mo/kgbw/day. The top dose level of
60 mgMo/kgbw/day is at least 20,000 times the normal human die-
tary exposure of 1–2 lg Mo/kgbw/day (Turnlund and Friberg,
2007). The dietary route of exposure was chosen because this is
the normal route of human exposure and the diets were shown
to be palatable in the 28-day study, producing substantial dose-re-
lated increases in serum molybdenum levels.2.4. Clinical observations
All animals were observed in their cages twice daily for mortal-
ity and general condition. During the treatment period, all animals
were observed for signs of toxic and pharmacological effects at
least twice daily. Animals were removed from their cages and
examined once pretest and weekly during the study period (except
examinations were performed twice during the ﬁrst week of the
recovery period). Examinations included observations of skin and
fur, eyes and mucous membranes, respiratory and circulatory ef-
fects, autonomic effects such as salivation, central nervous system
effects, including tremors and convulsions, changes in the level of
motor activity, gait and posture, reactivity to handling or sensory
stimuli, grip strength, and stereotypies or bizarre behavior.2.5. Ophthalmic examination
An ophthalmic examination was performed on all animals at
pretest and at the termination of the treatment period. The cornea,
anterior chamber, lens, iris, vitreous humor, retina, and optic disc
were examined by indirect ophthalmoscopy.2.6. Body weight and food consumption
Animals were removed from their cages and weighed twice pre-
test, weekly during the study and terminally (after fasting) just
prior to necropsy. Food consumption was measured pretest, at
Days 2, 4, and 7 during the ﬁrst week of treatment, and weekly
(at 6 day intervals) thereafter. The amount of food consumed over
a 6-day period during the week was used to determine feed con-
centration calculations for the following week for the ﬁrst 4 weeks
and every other week during the rest of the study.2.7. Hematology and blood chemistry
Blood samples were collected via the jugular vein (unanesthe-
tized or lightly anesthetized with isofuorane) or orbital sinus
(lightly anesthetized with isoﬂuorane) using dipotassium EDTA
(for hematological evaluation) or sodium citrate (for coagulation
studies) as an anticoagulant or no anticoagulant (for clinical chem-
istry). Animals were fasted overnight prior to blood collection. The
following hematological parameters were evaluated on a Bayer Ad-
via 120 hematology analyzer: hemoglobin concentration, hemato-
crit, erythrocyte count, platelet count, mean corpuscular volume,
mean corpuscular hemoglobin, mean corpuscular hemoglobin con-
centration, red cell distribution width, total leukocyte count, retic-
ulocyte count, and differential leukocyte count. Coagulation
parameters (prothrombin time and activated partial thrombo-
plastin time) were determined on a mechanical clot detection sys-
tem (STA Compact, Diagnostica Stago Products).
The following clinical chemistry parameters were determined
on a Hitachi 917 chemistry analyzer: aspartate aminotransferase,
alanine aminotransferase, alkaline phosphatase, blood urea nitro-
gen, creatinine, glucose, cholesterol, triglycerides, total protein,
albumin, uric acid, total bilirubin, sodium, potassium, chloride, cal-
cium, and inorganic phosphorus.2.8. Vaginal cytology/estrus cycles
Daily vaginal smears were taken from each female at approxi-
mately the same time each day and stage of estrus determined
for 3 weeks starting after completing 6 weeks of treatment. The
overall pattern of each female was characterized as regularly cy-
cling (having recurring 4–5 day cycles), irregularly cycling (having
cycles with a period of diestrus longer than 3 days or a period of
corniﬁcation longer than 2 days), or not cycling (having prolonged
periods of either vaginal corniﬁcation or leukocytic smears). Cycle
length was deﬁned as the number of days from one estrus to the
next. Incomplete cycles were not included in calculating the mean
cycle length.
2.9. Sperm evaluation
Sperm evaluations were performed as outlined in OECD TG 416.
All surviving male animals were processed for sperm counts and
sperm motility at the terminal sacriﬁce and the recovery sacriﬁce
using a Hamilton Thorne IVOS sperm analyzer. For sperm and sper-
matid counts, homogenized samples of the right caudal epididymis
and the right testis, respectively, were stained and examined; for
each stained preparation, 10 ﬁelds were counted. For sperm motil-
ity, the right vas deferens of all surviving males was excised and
placed in a pre-warmed solution of phosphate buffered saline
and 7.5% bovine serum albumin fraction V in Medium 199. After
a swim-out period, motility was evaluated using at least 200 sperm
and or ﬁve microscope ﬁeld images. Two sperm morphology slides
were prepared for all surviving males at terminal sacriﬁce and
recovery sacriﬁce; approximately 200 sperm per animal within
the 2 slides were evaluated.
2.10. Necropsy
All animals were fasted overnight prior to necropsy and eutha-
nized by carbon dioxide inhalation followed by exsanguination. All
animals were subject to macroscopic examination, which included
external surface and all oriﬁces, the external surfaces of the brain
and spinal cord, the organs and tissues of the cranial, thoracic,
abdominal and pelvic cavities and neck, and the remainder of the
carcass.
2.11. Organ weights
Absolute and relative organ weights (based on terminal body
weights) were determined for the adrenal glands, brain, epididy-
mides, heart, kidneys, liver, ovaries, pituitary gland, prostate gland
and seminal vesicles, spleen, testes, thymus, thyroid/parathyroid
glands, and uterus with cervix.
2.12. Histopathology
All organs and tissues obtained during necropsy were
preserved. Slides of these organs and tissues were prepared and
examined microscopically for all Group 1 (control) and Group 4
(high-dose) animals sacriﬁced at termination of the treatment per-
iod. In addition, the adrenal glands from males and the kidneys
from females in Groups 2 and 3, sacriﬁced at termination of the
treatment period, and from animals in Groups 1 and 4 sacriﬁced
at the end of the recovery period were examined microscopically.
2.13. Elemental analysis of serum, whole blood, liver and kidney
Blood and serum samples were taken from 10 rats/sex/group
and analyzed for molybdenum, copper, zinc, manganese, iron, co-
balt and selenium at weeks 4 (serum only) and 12 (serum and
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the recovery groups (serum only). Liver and kidney samples from
10 rats/sex/group were collected at the end of the treatment period
and the recovery period, and they were ﬂash frozen in liquid nitro-
gen and shipped on dry ice to the analytical laboratory for analysis
of the same elements as the serum samples. Serum, whole blood,
and tissues were analyzed for molybdenum and the other elements
at Michigan State University (East Lansing, MI) using a validated
inductively coupled plasma mass spectrometry (ICP-MS; Agilent
7500ce) method. The same laboratory and instrument was also
used to analyze the feed samples.
2.14. Statistical analysis
Continuous data, including body weights, food consumption,
hematology and clinical chemistry parameters, organ weights
and sperm analysis, were subjected to a Bartlett’s test for variance
homogeneity (Bartlett, 1937). If this was not signiﬁcant at the 1%
level, then parametric methods were applied using either Wil-
liams’ test (Williams, 1971, 1972) or Dunnett’s test (Dunnett,
1955, 1964). For non-continuous data, statistical tests were ranked
and examined by the Kruskal–Wallis test (Kruskal and Wallis,
1952, 1953). If signiﬁcant, the Wilcoxon rank sum test (Wilcoxon,
1945) was applied for comparison with the vehicle control group.
For analyses of serum, whole blood and tissue levels of metals
and other elements in the 90-day study, one-sided pairwise com-
parisons of each treatment group with their respective control
were conducted using the R software package version 2.14.1 (R
Development Core Team, 2011).3. Results
3.1. Analysis of diets
Chemical analysis conﬁrmed that the diets were of appropriate
concentration of molybdenum and that homogeneous dietary mix-
tures were administered. Mean analytical concentrations of
molybdenum in the diets were 91–102% of the nominal concentra-
tions. Exposure to the test substance was generally comparable to
the targeted dose levels, but with the males it was consistently less
than intended and with the females consistently more than in-
tended. Speciﬁcally, the actual mean intake of molybdenum at
the nominal dose levels of 5, 17, and 60 mgMo/kgbw/day was
4.5, 15.1, and 54.8 mg Mo/kgbw/day, respectively, among males
and 5.4, 19.0, and 65.2 mg Mo/kgbw/day, respectively, among fe-
males, giving overall mean intakes of 5.0, 17.1 and 60.0 mg Mo/
kgbw/day.
3.2. Mortality and clinical observations
One male in the group given 60 mg Mo/kgbw/day was found
dead on Day 47. There were no clinical signs prior to death and
no macroscopic or microscopic ﬁndings to explain the cause of
death. This single death was considered incidental and unrelated
to the administration of the test substance. There was no mortality
in any other groups. There were no treatment-related clinical signs
or ocular abnormalities in any of the animals.
3.3. Body weight and food consumption
During the 90-day treatment phase, statistically signiﬁcant de-
creases in body weight gain compared to controls were observed in
males and females exposed to 60 mg Mo/kgbw/day beginning as
early as weeks 1 and 6, respectively (Figs. 1 and 2). At the end of
the 90-day treatment period, the ﬁnal body weights of males andfemales given 60 mgMo/kgbw/day were 15.1% (p < 0.001) and
5.6% (not statistically signiﬁcant) less, respectively, than their
respective control values. During the 60-day recovery phase, the
males in the group given 60 mg Mo/kgbw/day showed statistically
signiﬁcant increases in body weight gains at each weekly interval,
but the absolute body weight was still signiﬁcantly less than con-
trols (by 9.5%; p < 0.05) at the end of the recovery phase. There
were no treatment-related effects on body weight or body weight
gain among the males or females given 5 or 17 mg Mo/kgbw/day.
In males given 60 mgMo/kgbw/day, food consumption was sta-
tistically signiﬁcantly decreased on numerous occasions through-
out the treatment period. Otherwise, compared to controls, no
consistent difference in food consumption was observed in any
of the other groups of males or females receiving the test material.
At 60 mgMo/kgbw/day, food conversion efﬁciency was signiﬁcantly
reduced during the treatment period, particularly among the
males, suggesting that some interference with nutrition, as well
as reduced food consumption, may have played a role in reduced
body weight gain.
3.4. Hematology and clinical chemistry
There were no effects on hematological parameters, apart from
a marginal (61 s), statistically signiﬁcantly shorter prothrombin
times in males receiving 5, 17 or 60 mgMo/kgbw/day. These
changes were not considered to be related to the administration
of the test substance because they were slight, not dose-related,
and not observed in females. No signiﬁcant difference from con-
trols was seen for activated partial thromboplastin time in any
group of males or females.
The results of clinical biochemistry evaluation revealed statisti-
cally signiﬁcant decreases in total protein and calcium at
60 mg Mo/kgbw/day in males, but not in females. Creatinine and
uric acid levels were statistically signiﬁcantly reduced compared
to controls among females at all dose levels, but a similar effect
was not observed in males. The changes in clinical chemistry
parameters were not considered to be treatment-related because
they were small in magnitude, not dose-related, due to outliers
in control animals, and/or were consistent with normal biological
variability.
3.5. Estrus cycles and sperm evaluation
There were no test substance-related effects on vaginal cytology
or estrus cycles when observed during weeks 7–9 of the treatment
phase (Table 1). No signiﬁcant differences were observed in the
mean length of the cycle or the mean number of cycles among
groups of females exposed to molybdenum compared to controls.
One female with an irregular cycle was observed in the control
group and in each treated group.
In males, no effect of treatment was observed on spermatid or
sperm counts (Table 2), or on sperm morphology. No signiﬁcant ef-
fect on overall spermmotility was observed at any dose level at the
terminal sacriﬁce, although the 60 mgMo/kgbw/day males had a
slight but statistically signiﬁcant decrease in progressively motile
sperm at the terminal sacriﬁce (59.0% vs. 69.4% in controls). This
slight decrease in progressively motile sperm at the high dose
was likely attributable to the control group having a value that ap-
proached the upper limit for this parameter among historical con-
trol groups (mean of 59.8 ± 16.2%) and was therefore not
considered a test substance-related ﬁnding. The spermmorpholog-
ical evaluation found no signiﬁcant effect in any group on the per-
cent normal sperm or the percent of individual abnormalities (i.e.,
decapitated, abnormal head, abnormal neck, abnormal tail, mid-
tail blob). At the end of the recovery period, there was no signiﬁ-
cant effect on any sperm parameter.
Fig. 1. Mean body weights of male rats in 90 day toxicity study of sodium molybdate dihydrate with 60 day recovery period.
Fig. 2. Mean body weights of female rats in 90 day toxicity study of sodium molybdate with 60 day recovery period.
Table 1
Length of estrus cycles, number of cycles and number of females with irregular cycles among female rats in the 90 day toxicity study of sodium molybdate dihydrate.a
Dose (mg Mo/kgbw/day) Mean length of estrus cycle, days (No. of rats) Mean number of cycles (No. of rats) Number of females with irregular cycles
0 4.0 ± 0.11 (19)b 4.3 ± 0.7 (19)b 1
5 4.1 ± 0.17 (10) 3.9 ± 0.7 (10) 1
17 4.0 ± 0.26 (10) 4.1 ± 0.9 (10) 1
60 4.1 ± 0.29 (20) 4.0 ± 0.9 (20) 1
a Daily vaginal smears were taken from each female at approximately the same time each day and stage of estrus determined for 3 weeks starting after completing 6 weeks
of treatment.
b Mean ± standard deviation (n).
Table 2
Mean sperm motility and counts among male rats at the terminal sacriﬁce in the 90 day toxicity study of sodium molybdate dihydrate (10 animals per group).
Dose (mg Mo/kgbw/day) Right vas deferens Right cauda epididymis Right testis
Motile sperm (%) Progressively motile sperm (%) Weight (g) Sperm count (millions/g) Weight (g) Spermatid count (millions/g)
0 Mean ± SD 97.3 69.4 0.374 542.7 1.710 91.8
2.6 10.9 0.036 120.5 0.080 21.5
5 Mean ± SD 97.9 60.4 0.399 640.1 1.869 91.4
2.0 14.4 0.045 97.4 0.169 13.9
17 Mean ± SD 98.0 65.6 0.393 649.0 1.797 89.4
1.4 8.1 0.038 152.2 0.135 18.7
60 Mean ± SD 98.1 59.0a 0.374 520.9 1.745 84.7
1.3 6.8 0.032 132.1 0.132 17.1
a Signiﬁcantly different from the control group (p < 0.05).
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Table 3
Absolute and relative organ weights in male rats fed sodium molybdate dihydrate for 90 days.
Organ Dose group (mg Mo/kgbw/day)
0 5 17 60
Number of rats 10 10 10 10
Final body weight 566.8 ± 46.8a 556.4 ± 40.2 550.7 ± 45.1 482.4 ± 29.5c
Absolute organ weight (g, unless otherwise noted)
Brain 2.19 ± 0.08 2.15 ± 0.12 2.10 ± 0.08b 2.07 ± 0.08c
Kidneys 3.34 ± 0.34 3.34 ± 0.29 3.23 ± 0.23 3.11 ± 0.19
Liver 14.79 ± 1.26 15.13 ± 1.41 14.91 ± 1.67 12.07 ± 0.69c
Heart 1.77 ± 0.25 1.65 ± 0.11 1.62 ± 0.18 1.50 ± 0.13c
Spleen 0.99 ± 0.20 0.91 ± 0.11 0.99 ± 0.20 0.79 ± 0.11c
Thymus 0.266 ± 0.088 0.283 ± 0.081 0.257 ± 0.083 0.252 ± 0.072
Thyroid/para (mg) 32.7 ± 5.9 34.0 ± 8.5 32.2 ± 6.2 31.1 ± 4.9
Adrenal glands (mg) 72.0 ± 9.3 66.5 ± 8.7 69.7 ± 11.9 69.0 ± 9.8
Pituitary gland (mg) 18.8 ± 1.9 16.1 ± 1.5b 16.9 ± 2.0b 18.1 ± 2.0b
Testes 3.43 ± 0.17 3.63 ± 0.40 3.60 ± 0.26 3.55 ± 0.26
Prostate w/semis 3.20 ± 0.30 3.30 ± 0.25 3.26 ± 0.38 3.09 ± 0.26
Epididymides 1.58 ± 0.05 1.64 ± 0.20 1.67 ± 0.12 1.59 ± 0.15
Relative organ weight (% body weight, unless otherwise noted)
Brain 0.388 ± 0.025 0.388 ± 0.032 0.383 ± 0.030 0.431 ± 0.027c
Kidneys 0.591 ± 0.060 0.600 ± 0.043 0.588 ± 0.046 0.646 ± 0.035b
Liver 2.61 ± 0.16 2.72 ± 0.25 2.71 ± 0.20 2.51 ± 0.17
Heart 0.315 ± 0.052 0.296 ± 0.015 0.296 ± 0.032 0.311 ± 0.029
Spleen 0.176 ± 0.039 0.165 ± 0.027 0.180 ± 0.033 0.164 ± 0.022
Thymus 0.046 ± 0.013 0.051 ± 0.015 0.046 ± 0.014 0.052 ± 0.014
Thyroid/para (103%) 5.8 ± 1.1 6.1 ± 1.2 5.8 ± 0.8 6.4 ± 0.8
Adrenal glands (103%) 12.7 ± 1.6 12.0 ± 1.5 12.7 ± 2.1 14.3 ± 1.9
Pituitary gland (103%) 3.3 ± 0.3 2.9 ± 0.2 3.1 ± 0.4 3.7 ± 0.3c
Testes 0.609 ± 0.047 0.654 ± 0.080 0.655 ± 0.042 0.737 ± 0.066c
Prostate w/semis 0.566 ± 0.052 0.594 ± 0.049 0.599 ± 0.112 0.643 ± 0.074b
Epididymides 0.280 ± 0.022 0.296 ± 0.045 0.305 ± 0.035 0.330 ± 0.039c
a Mean ± standard deviation.
b Signiﬁcantly different from control group at p < 0.05.
c Signiﬁcantly different from control group at p < 0.01.
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In males given 60 mg Mo/kgbw/day, absolute organ weights
were statistically signiﬁcantly decreased compared to control val-
ues for the brain, liver, heart, spleen and pituitary, presumably due
to reduced body weight since no signiﬁcant decrease in any organ
weight relative to body weight was observed (Table 3). A small, but
statistically signiﬁcant, decrease in absolute brain weight was also
seen in males at 17 mg Mo/kgbw/day. Brain weight is typically con-
served when body weight decreases. However, the decreases in
absolute brain weight were not considered biologically signiﬁcant,
because the percent reduction in brain weight (5% at the high dose)
was only one-third of the percent reduction in body weight (15% at
the high dose), there was no evidence of any histopathological ef-
fects in the brain, and a similar effect was not observed in females.
Statistically signiﬁcant decreases in absolute pituitary weight were
also observed in males at 5 and 17 mg Mo/kgbw/day but were con-
sidered spurious based on the small magnitude of the effect, the
absence of dose–response, and a lack of correlative histopathologic
ﬁndings.
In females, which exhibited less evidence of reduced
body weight, there were no signiﬁcant effects on organ
weights at any dose level, with the exception of the thyroid
(Table 4).
Females given 5, 17 or 60 mgMo/kgbw/day had small but sta-
tistically signiﬁcant decreases in absolute and relative
thyroid weights; however, these differences were not
considered treatment-related since the magnitude of the de-
creases were small and not dose-related, there was no histopa-
thological correlate, a similar effect was not observed in males,
and the concurrent control value was high compared to histori-
cal controls.3.7. Pathology
There were no macroscopic ﬁndings at necropsy related to
administration of the test material. Microscopic ﬁndings consid-
ered possibly to be related to the test substance were limited to
changes in the kidneys in females at 60 mg Mo/kgbw/day. Two fe-
males from the 60 mg Mo/kgbw/day dose group showed slight dif-
fuse hyperplasia of the proximal tubules in the kidney. Although
this ﬁnding was present in only two female rats, it is uncommon
as a background ﬁnding in this age of animal, and therefore it
was presumed to be substance-related. Following the 60-day
recovery phase, proximal tubule hyperplasia in the kidneys of fe-
males administered 60 mg Mo/kgbw/day was not observed in any
of the animals.
In males, there were increased incidences of ‘minimal’ and
‘slight’ vacuolation in the cells of the zona fasiculata in the adrenal
cortex of males given 5 or 60 mgMo/kgbw/day. A dose–response
relationship was not apparent, and this ﬁnding was considered
incidental and unrelated to test substance administration. In-
creased cortical vacuolation of the adrenal is a relatively common
background ﬁnding in rats that generally reﬂects normal but vari-
able physiological activity. There were no test substance-related
changes in the male or female reproductive tissues.3.8. Serum, blood and tissue concentrations of molybdenum and other
elements
Dietary administration of sodium molybdate dihydrate pro-
duced a dose-related increase in molybdenum concentrations in
the serum and whole blood (Table 5). The males had higher serum
and/or whole blood levels of molybdenum than the females (23%
on average for the three treated groups) at all dose levels at both
Table 4
Absolute and relative organ weights in female rats fed sodium molybdate dihydrate for 90 days.
Organ Dose group (mg Mo/kgbw/day)
0 5 17 60
Number of rats 10 10 10 10
Final body weight 282.9 ± 13.2a 298.3 ± 31.3 298.6 ± 31.0 266.9 ± 22.5
Absolute organ weight (g, unless otherwise noted)
Brain 1.94 ± 0.08 1.92 ± 0.09 1.94 ± 0.08 1.90 ± 0.08
Kidneys 1.88 ± 0.17 1.96 ± 0.27 1.90 ± 0.17 1.83 ± 0.18
Liver 7.62 ± 0.90 7.90 ± 1.18 7.67 ± 0.70 7.07 ± 0.67
Heart 1.06 ± 0.06 1.11 ± 0.16 1.08 ± 0.11 1.00 ± 0.12
Spleen 0.54 ± 0.07 0.54 ± 0.09 0.53 ± 0.06 0.48 ± 0.09
Thymus 0.269 ± 0.071 0.304 ± 0.065 0.252 ± 0.069 0.247 ± 0.073
Thyroid/para (mg) 28.5 ± 4.4 25.0 ± 3.0b 24.9 ± 3.0b 25.1 ± 4.1b
Adrenal glands (mg) 66.6 ± 13.6 65.4 ± 15.7 67.7 ± 12.4 61.1 ± 8.5
Pituitary gland (mg) 22.1 ± 2.8 24.9 ± 4.9 21.4 ± 5.3 21.5 ± 3.5
Ovaries 0.087 ± 0.018 0.075 ± 0.014 0.082 ± 0.013 0.077 ± 0.017
Uterus w/ cervix 0.887 ± 0.454 0.697 ± 0.142 0.739 ± 0.180 0.830 ± 0.195
Relative organ weight (% body weight, unless otherwise noted)
Brain 0.687 ± 0.039 0.650 ± 0.062 0.657 ± 0.086 0.716 ± 0.053
Kidneys 0.666 ± 0.046 0.658 ± 0.060 0.640 ± 0.074 0.686 ± 0.062
Liver 2.69 ± 0.28 2.64 ± 0.20 2.58 ± 0.16 2.65 ± 0.11
Heart 0.375 ± 0.020 0.371 ± 0.031 0.362 ± 0.030 0.374 ± 0.023
Spleen 0.192 ± 0.024 0.181 ± 0.031 0.177 ± 0.013 0.179 ± 0.028
Thymus 0.095 ± 0.024 0.101 ± 0.015 0.084 ± 0.020 0.093 ± 0.026
Thyroid/para (103%) 10.1 ± 1.6 8.5 ± 1.2b 8.4 ± 1.0b 9.4 ± 1.6b
Adrenal glands (103%) 23.6 ± 5.1 22.0 ± 5.1 23.1 ± 5.9 22.9 ± 2.4
Pituitary gland (103%) 7.8 ± 1.0 8.3 ± 1.1 7.3 ± 2.0 8.0 ± 0.9
Ovaries (103%) 30.8 ± 6.2 25.5 ± 5.8 27.7 ± 5.9 29.2 ± 7.5
Uterus w/ cervix 0.315 ± 0.166 0.236 ± 0.053 0.249 ± 0.058 0.312 ± 0.075
a Mean ± standard deviation .
b Signiﬁcantly different from control group at p < 0.05.
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plained by the test substance intake results that showed the fe-
males had higher actual intake levels (0, 5.4, 19.0, and
65.2 mg Mo/kgbw/day) compared to males (0, 4.5, 15.1, and
54.8 mg Mo/kgbw/day) at the nominal dose levels of 0, 5, 17, and
60 mgMo/kgbw/day.
There was no signiﬁcant accumulation of molybdenum in the
serum, since the week 12 serum results were only slightly greater
than week 4 serum results. Compared to serum levels, the whole
blood levels in week 12 were consistently lower (55% on average
for the three treated groups, both sexes) suggesting that the major-
ity of the molybdenum was in the plasma rather than in the red
blood cells. During the recovery period, there was a rapid and sub-
stantial reduction in serum molybdenum concentrations at Days 2
and 7 after cessation of treatment in the group given 60 mg Mo/
kgbw/day.Table 5
Molybdenum concentrations (mean ± standard deviation) in serum, whole blood, liver and
Dose
(mg Mo/
kgbw/day)
Serum week
4 (ng/mL)
Serum week
12 (ng/mL)
Whole blood
week 12 (ng/
mL)
Serum Day 2
recovery (ng/
mL)
Ser
reco
mL
Male
0a 18.72 ± 3.57 19.44 ± 7.18 11.97 ± 1.68 19.10 ± 4.92 20.6
5 1332 ± 379.0 1309 ± 215.5 912.5 ± 212.0 N.D. N.D
17 4688 ± 616.9 4674 ± 1670 2930 ± 778.3 N.D. N.D
60 16277 ± 3660 18497 ± 4339 9903 ± 2291 4382 ± 2365 242
Female
0a 19.86 ± 10.65 17.93 ± 3.47 11.11 ± 2.26 15.14 ± 2.06 33.3
5 991.9 ± 461.3 1121 ± 460.0 720.4 ± 329.1 N.D. N.D
17 3371 ± 710.4 4312 ± 985.7 2628 ± 479.0 N.D. N.D
60 13176 ± 3905 15532 ± 5938 7736 ± 2431 6447 ± 5431 284
N.D. = not determined.
a Group 1 animals received approximately 0.08 mg Mo/kgbw/day from the diet.Dose-related increases in liver and kidney concentrations of
molybdenum (dry weight) were observed at the termination of
exposure (Table 5). In contrast to the results in serum and blood,
the concentrations of molybdenum in the liver and kidney were
higher in females than males at all dose levels. Sixty days after
exposure, nearly complete recovery to control molybdenum con-
centrations was observed in the liver, but not in the kidney.
Consistent with the well-known interaction between molybde-
num and copper levels in the body, statistically signiﬁcant in-
creases in copper concentrations in the serum, whole blood, liver
and kidney were observed in both males and females given
60 mg Mo/kgbw/day (Table 6). In the middle dose group
(17 mg Mo/kgbw/day), the levels of copper in the serum in males,
and serum, liver and kidney in females were also signiﬁcantly in-
creased, although to a lesser extent than observed at the high dose.
At the low dose (5 mg Mo/kgbw/day), the only statistically signiﬁ-kidney in rats given sodium molybdate dihydrate in the diet.
um Day 7
very (ng/
)
Liver Terminal
sacriﬁce (lg/
g)
Kidney
Terminal
sacriﬁce (lg/g)
Liver End of
recovery (lg/
g)
Kidney end of
recovery (lg/
g)
2 ± 4.89 2.22 ± 0.19 0.93 ± 0.16 1.88 ± 0.40 0.91 ± 0.15
. 2.53 ± 0.28 2.30 ± 0.79 N.D. N.D.
. 4.00 ± 1.23 9.52 ± 6.91 N.D. N.D.
6 ± 1187 11.49 ± 5.35 41.66 ± 31.41 2.30 ± 0.36 7.04 ± 5.93
7 ± 49.15 2.46 ± 0.28 0.94 ± 0.13 2.71 ± 0.18 0.97 ± 0.16
. 3.51 ± 0.45 3.83 ± 2.74 N.D. N.D.
. 4.92 ± 0.62 10.94 ± 4.36 N.D. N.D.
2 ± 2201 12.99 ± 3.65 55.04 ± 27.49 4.58 ± 2.29 16.86 ± 18.29
Table 6
Copper concentrations (mean ± standard deviation) in serum, whole blood, liver and kidney in rats given sodium molybdate dihydrate in the diet.
Dose
(mg Mo/
kgbw/day)
Serum
week 4 (ng/
mL)
Serum
week 12
(ng/mL)
Whole blood
week 12 (ng/
mL)
Serum Day 2
recovery (ng/
mL)
Serum Day 7
recovery (ng/
mL)
Liver (lg/g)
terminal
sacriﬁce
Kidney (lg/g)
terminal
Sacriﬁce
Liver (lg/g)
end of
recovery
Kidney (lg/g)
end of
recovery
Male
0 1.26 ± 0.29 1.43 ± 0.30 1.12 ± 0.15 1.91 ± 1.22 1.49 ± 0.21 16.96 ± 1.93 30.19 ± 10.59 14.47 ± 2.64 26.31 ± 10.36
5 1.47 ± 0.18 1.62 ± 0.27 1.12 ± 0.14 N.D. N.D. 19.47 ± 2.97 31.13 ± 6.28 N.D. N.D.
17 1.74 ± 0.39b 2.10 ± 0.68a 1.25 ± 0.28 N.D. N.D. 18.77 ± 3.00 39.70 ± 13.67 N.D. N.D.
60 4.51 ± 2.21b 5.79 ± 2.91b 2.53 ± 1.21b 4.14 ± 1.44b 2.92 ± 0.69b 26.32 ± 7.55a 86.04 ± 52.93a 15.14 ± 1.25 43.39 ± 16.77a
Female
0 1.77 ± 0.21 1.95 ± 0.23 1.32 ± 0.15 2.03 ± 0.48 1.91 ± 0.19 19.21 ± 2.06 43.54 ± 11.39 19.16 ± 1.78 43.84 ± 19.83
5 1.97 ± 0.26 2.06 ± 0.34 1.34 ± 0.23 N.D. N.D. 23.85 ± 3.62a 64.34 ± 24.17 N.D. N.D.
17 2.12 ± 0.47 2.56 ± 0.72a 1.40 ± 0.24 N.D. N.D. 25.16 ± 5.06a 67.06 ± 23.77a N.D. N.D.
60 4.51 ± 2.17b 6.63 ± 4.36b 2.14 ± 0.50b 7.02 ± 4.16b 3.56 ± 1.50b 36.32 ± 7.00b 138.72 ± 56.34b 22.34 ± 4.87 74.33 ± 40.12
N.D. = not determined.
a Difference from relative control group statistically signiﬁcant p < 0.05.
b Difference from relative control group statistically signiﬁcant p < 0.001.
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liver of females.
4. Discussion
This study is the ﬁrst published 90-day study of ingested
molybdenum in animals performed according to current guidelines
(OECD TG 408) and under GLP conditions. The study results did not
demonstrate toxicity in rats given sodium molybdate dihydrate in
the diet at dose levels of 5 and 17 mg Mo/kg/day for 90 days. How-
ever, at the highest dose level (60 mg Mo/kgbw/day), toxicity was
evident in both males and females. This high dose is at least
20,000-fold higher than the current estimates of human intake of
1–2 lg Mo/kgbw/day derived from molybdenum-containing food
and water (Turnlund and Friberg, 2007).
At the end of the 90-day exposure period, the high dose males
and females weighed 15.1% and 5.6% less, respectively, than con-
trols. At the high dose, the decreased growth observed in males
was associated with decreased food consumption, and there was
evidence of reduced food conversion efﬁciency in both males and
females. In earlier toxicity studies in rats, exposure to molybde-
num also produced a decreased body weight gain; however, pair-
feeding experiments demonstrated that reduced food intake was
not the primary cause of weight loss produced by exposure to
molybdenum (Arrington et al., 1965). The greater effect on the
growth of males compared to females at the high dose is not due
to a difference in the ingested dose of Mo since the actual mean
dose of Mo ingested by high-dose males and females was approx-
imately 55 and 65 mg Mo/kgbw/day, respectively. However, the
greater effect on the growth of males may be related to the fact
that serum levels of Mo at the high dose were slightly higher
(about 23% on average) among males compared to females.
Histopathological evaluation revealed test substance-related
ﬁndings in the kidneys (slight diffuse hyperplasia of the proximal
tubules) of two 60 mg Mo/kgbw/day females at the terminal sacri-
ﬁce, which were not present in females sacriﬁced at the end of
the recovery period of 60 days. No other microscopic effects were
observed that appeared to be treatment-related. The effect of
molybdenum on renal function was previously studied in male rats
given 40 or 80 mg Mo/kgbw/day by gavage for 8 weeks (Bompart
et al., 1990). In that gavage study, nephrotoxicity and decreased
body weight were observed at 80 mg Mo/kg/day, but not at
40 mgMo/kgbw/day. It is interesting to note that excretion of
molybdenum occurs predominantly via the kidneys, which exert
homeostatic regulation over molybdenum balance (CDC, 2012).
Whether the elevated concentrations of copper observed in the
kidneys of the high dose females in the present study (138.7 lg/gvs. 43.5 lg/g in controls) may have played some role in the histo-
pathological changes in the kidneys is not known, although the
kidney is a target organ for copper toxicity (Hebert, 1993).
The results of the current study do not conﬁrm earlier reports of
reproductive effects on male and female rats exposed to molybde-
num. Pandey and Singh (2002) reported adverse effects of sodium
molybdate on sperm count, motility and morphology in Druckery
rats administered sodium molybdate by gavage at dose levels of
12 and 20 mg Mo/kgbw/day ﬁve days per week for a 60 day period.
In contrast, no adverse treatment-related effects on the testes
(weight or histopathology), sperm counts, motility or morphology
were seen in the current study in rats administered larger oral
doses (up to 60 mg Mo/kgbw/day) for a longer duration (90 days).
Possible factors contributing to the discrepancy in ﬁndings be-
tween the two studies include the different strains of rats and
the different routes of administration (gavage vs. diet), although
no signiﬁcant difference in toxicity was observed between the ga-
vage and dietary routes of exposure in our 28-day range-ﬁnder
study. However, the Pandey and Singh (2002) study was poorly re-
ported with no clear description of the effects on the testes or the
actual numbers of animals affected, and there were apparent
inconsistencies in the statistical analyses.
The results of the current study are also inconsistent with those
of Fungwe et al. (1990), who reported a signiﬁcantly prolonged
length of the estrus cycle in rats exposed to molybdenum in the
drinking water for 6 weeks (Fungwe et al., 1990). Although Fungwe
et al. (1990) did not describe the dose levels in terms other than
the concentration of molybdenum in the drinking water, others
have estimated that the NOAEL and LOAEL for estrus cycle effects
were 0.9 and 1.6 mg Mo/kgbw/day, respectively, in this study. In
contrast, the results of the present study showed no effect on the
estrus cycles in rats given molybdenum in the diet for 90 days at
dose levels up to 60 mg Mo/kgbw/day. The group size was larger
in the current study (n = 10–20) than in the Fungwe et al. (1990)
study (n = 6). Both studies used Sprague–Dawley rats, and it is un-
likely that the difference in the routes of exposure (diet vs. drink-
ing water) would explain such different ﬁndings. Other studies in
animals have demonstrated that the effects of molybdenum on
growth are more pronounced under situations where dietary cop-
per intake is low (EPA, 2003). The dietary concentration of copper
was determined to be adequate in the present study, but the die-
tary concentration of copper was not described in the Fungwe
et al. (1990) study. The inability of the present study to conﬁrm
the effects of molybdenum on the estrus cycle reported by Fungwe
et al. (1990) is important because that study has been used as the
critical study in risk assessments of molybdenum (Vyskocil and
Viau, 1999; IOM, 2001; EPA, 2003).
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study, as evidenced by the substantial dose-related increases of
molybdenum in the serum, blood, liver and kidney. For example,
in the high dose males at the termination of the 90-day exposure
period, the molybdenum concentrations in serum, blood, liver
and kidney were approximately 950, 825, 5.2 and 45 times greater
than the respective control values. Neither Fungwe et al. (1990)
nor Pandey and Singh (2002) measured the concentrations of
molybdenum in serum, blood or tissues, precluding direct
comparisons with the molybdenum levels observed in the present
study.
No evidence of a treatment-related effect on the reproductive
organs or secondary reproductive organs was reported in a 90-
day and a 2-year repeat-dose toxicity study of inhaled molybde-
num trioxide, a less soluble molybdenum substance than is sodium
molybdate dihydrate, in both mice and a different strain of rats
(NTP, 1997). Although the test substance, strain of rats, and expo-
sure route used by NTP differed from that employed in the present
study, the substance circulating in the blood (i.e., molybdate ion)
would be the same for both substances (Mitchell, 2009). Thus, sys-
temic exposure to molybdenum may be compared based on blood
(or serum) concentrations of molybdenum. The mean blood
molybdenum concentration in male rats at the highest exposure
concentration (100 mg/m3 molybdenum trioxide) in the NTP 2-
year inhalation study of molybdenum trioxide was about 60% of
the mean blood molybdenum concentration observed among high
dose males in the current 90-day dietary study, showing substan-
tial absorption of molybdenum in the NTP study and with no ad-
verse effects observed on the reproductive organs.
In the current 90-day toxicity study, ingestion of sodium
molybdate dihydrate produced dose-related increases in copper
levels in serum, blood, kidneys and liver. For example, at the end
of the 90-day exposure period, serum copper levels among high
dose males and females were 405% and 340%, respectively, of the
control values. Previous toxicity studies of molybdenum in rodents
have reported that high doses of molybdenum produced toxicity,
which was associated with very high blood and tissue levels of
copper. The copper, however, was tightly bound to carrier proteins
in the blood and tissues, and it was suggested that, despite the ele-
vated copper levels, the toxicity of molybdenum was actually re-
lated to a reduction in bioavailable copper (Compere et al., 1965;
Nederbragt, 1980; Nederbragt and van den Hamer, 1981; Neder-
bragt, 1982). Measuring the speciation, binding and excretion of
copper was beyond the scope of the present study. The changes
in copper levels at 5 and 17 mg Mo/kgbw/day were considered to
represent a physiological adaptation, not a toxic response, since
symptoms of toxicity attributable to the test material were not ob-
served and the tissue levels, even at the highest dose level were
well below those associated with toxicity in other studies (Hebert,
1993; Stern, 2010).5. Conclusion
In conclusion, dietary administration of sodium molybdate
dihydrate providing a dose of 60 mg Mo/kgbw/day for 90 days
clearly affected body weight gain in male and female rats, and
was associated with mild renal effects in females. Elevated levels
of molybdenum and copper were found in the serum, blood, liver
and kidneys of rats treated with 60 mg Mo/kgbw/day. Lower doses
of 5 and 17 mgMo/kgbw/day did not cause any treatment-related
toxicity. No treatment-related adverse effects on the reproductive
organ weights or histopathology, estrus cycles or sperm parame-
ters were observed at any dose level. Thus, the NOAEL for molyb-
denum in male and female rats was determined to be 17 mg Mo/
kgbw/day based on effects on reduced body weight gain in malesand females, and renal effects in two females at 60 mg Mo/kgbw/
day. The NOAEL for gonadal, sperm and estrus cycle effects was
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